218 results
Page 4 of 11
S-3ASR
faz0op9zptezqf2l2
10 Feb 21
Automatic shelf registration
6:04am
S-3ASR
EX-4.5
t8277 vbv
10 Feb 21
Automatic shelf registration
6:04am
S-3ASR
EX-4.6
nxhknf8b9l dby6fh326
10 Feb 21
Automatic shelf registration
6:04am
8-K
EX-99.1
xbx52rafau fxlj
8 Feb 21
Regulation FD Disclosure
4:09pm
8-K
EX-99.2
pw6esihte92w
8 Feb 21
Regulation FD Disclosure
4:09pm
8-K
i8rw19obqu3pu71dgd
6 Jan 21
Cassava Sciences Appoints Dr. James Kupiec as Chief Clinical Development Officer
4:39pm
8-K
EX-10.1
7uxxet0oifwdztbus
6 Jan 21
Cassava Sciences Appoints Dr. James Kupiec as Chief Clinical Development Officer
4:39pm
8-K
EX-99.1
4c15wbly95fa
6 Jan 21
Cassava Sciences Appoints Dr. James Kupiec as Chief Clinical Development Officer
4:39pm
424B5
fwle25lln3 kn8qx89w
16 Nov 20
Prospectus supplement for primary offering
12:21pm
8-K
EX-1.1
bhjjvwb2fh1mff
13 Nov 20
Cassava Sciences Announces Proposed Public Offering of Common Stock
4:36pm
424B5
sgb3u
12 Nov 20
Prospectus supplement for primary offering
4:57pm
8-K
EX-99.1
4eerzp4no v7w
9 Nov 20
Cassava Sciences Reports Third Quarter 2020 Financial Results
8:30am
8-K
EX-99.1
bylgvl5dwjken jq4
14 Sep 20
Regulation FD Disclosure
4:01pm
8-K
EX-99.2
ay7s5o7j6pecc l689v
14 Sep 20
Regulation FD Disclosure
4:01pm
8-K
EX-99.1
vlvsmcon16p91f8
12 Aug 20
Cassava Sciences Announces Second Quarter 2020 Financial Results and Mid-year Business Review
8:30am
8-K
EX-99.2
9qo0opmb
3 Jun 20
Regulation FD Disclosure
5:29pm
8-K
EX-99.1
2nt3q733 pf
15 May 20
Top-line Results from a Phase 2b Study of PTI-125 in Alzheimer’s Disease Does Not Meet Primary Endpoint
8:20am